Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Helyezés a részvények között #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Részvényárfolyam
$0.04443294
Utolsó szinkronizálás: 2026-09-24
Piaci kapitalizáció
$13.65M
Változás (1 nap)
0.00%
Változás (1 év)
-35.28%
Ország
AU
Kereskedés Noxopharm Limited (NOX)

Kategória

Healthcare
Noxopharm Limited (NOX) P/S aránya
P/S arány ekkor: September 2026 TTM: 0.00
Noxopharm Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 0.00. 2024 végén ez az arány 8.04 volt.
P/S arány története a(z) Noxopharm Limited esetén 2016 és 2026 között
P/S arány az év végén
Év P/S arány Változtassa meg
2026 (TTM) 0.00 -100.00%
2025 5.60 -30.33%
2024 8.04 284.34%
2023 2.09 -80.01%
2022 10.46 -65.53%
2021 30.35 1,000.90%
2020 2.76 -81.58%
2019 14.96 -78.61%
2018 69.96 -68.70%
2017 223.50 0.00%
2016 0.00 0.00%
P/S arány hasonló vállalatoknál vagy versenytársaknál
Vállalat P/S arány P/S arány különbség Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH